Citi raised the firm’s price target on Boston Scientific (BSX) to $122 from $107 and keeps a Buy rating on the shares. The company reported another strong quarter, meaningfully surpassing consensus, with four of its eight segments delivering double-digit growth, the analyst tells investors in a research note. The firm views Boston Scientific’s outlook as conservative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
Questions or Comments about the article? Write to editor@tipranks.com